Assessment of Chemo-Immunotherapy Regimens in Patients with Refractory or Relapsed Neuroblastoma: A Systematic Review with Meta-Analysis of Critical Oncological Outcomes.

J Clin Med · 2025 · PMC11818460 · PMID 39941606

Europe PMC DOI

hedged sentence

0.0400

closest p · 0.8× alpha

0.0400

boldest claim

The sentences

highly significantp = 0.04actually significant

The test for overall heterogeneity was highly significant (Q(4) = 10.14, p = 0.04), reflecting the notable variability in the results.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.